As Elon Musk moves to shutter the U.S. Agency for International Development, the agency’s support for the discovery of novel viruses in collaboration with the Wuhan Institute of Virology has come ...

Stifel Nicolaus analyst Alex Thompson CFA maintained a Buy rating on Spyre Therapeutics (SYRE – Research Report) today and set a price target of $71.00. The company’s shares closed last Friday ...

Try Now>> See today’s best-performing stocks on TipRanks >> Read More on SWTX: SpringWorks Therapeutics NewsMORE Related Stocks Indices Commodities Currencies Stocks ...

Ariceum Therapeutics (Ariceum), a private biotech company developing radiopharmaceutical products for the diagnosis and treatment of certain hard-to-treat cancers, today announced that the U.S. Food ...

On Monday, H.C. Wainwright downgraded Pliant Therapeutics (NASDAQ:PLRX) stock from Buy to Neutral following concerns about the safety of the company's lead drug candidate, bexotegrast. The stock ...

PRINCETON, N.J., Feb. 10, 2025 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (Nasdaq: GRCE), formerly Acasti Pharma Inc. (Grace Therapeutics or the Company), a late ...

(RTTNews) - Grace Therapeutics, Inc. (GRCE), a late-stage biopharma company, Monday said Phase 3 STRIVE-ON safety study met its primary goal. The STRIVE-ON study was designed to evaluate GTx-104 ...

Pliant Therapeutics shares fell sharply in pre-market trading Monday after it said it would pause its pulmonary fibrosis drug following a review by independent monitors. Shares traded 55% lower ...

Zeit Aktuelle Nachrichten 15:42 Grace Therapeutics meets main goal in late stage trial for its aneurysmal SAH treatment 14:35 Grace Therapeutics meldet positive Ergebnisse der Phase-3-Studie für ...

It's time for Super Bowl LIX. Prior to the Kansas City Chiefs and Philadelphia Eagles taking the field for the championship game, musician and Louisiana native Jon Batiste sang the national anthem ...